1st Quarter - Amendment

CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
—
Expenses
$200,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 20, 2009 — Replaced
1st Quarter - Amendment (this page) Jul 20, 2009 $200,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Oppose provisions in patent reform legislation (HR 1260/S 515) that would undermine certainty and weaken patent rights.

LobbyistCovered position, as disclosed
TODD E GILLENWATER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1260 (111th)

Medicare/Medicaid MMM

Address the consequences of the inappropriate applications of comparative effectiveness research when used simply as a cost containment mechanism.

LobbyistCovered position, as disclosed
TODD E GILLENWATER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Labor, Health and Human Services, and Education, and Related Agencies Appropriations for FY10, provisions on NIH and biodefense/pandemic funding, and math and science education program funding. Commerce, Justice, Science Appropriations for FY10, provisions on funding for NSF and for Professional Science Masters program.

LobbyistCovered position, as disclosed
TODD E GILLENWATER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Education EDU

Support funding for Professional Science Masters program.

LobbyistCovered position, as disclosed
TODD E GILLENWATER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

Labor, Health and Human Services, and Education, and Related Agencies Appropriations for FY10, provisions on NIH and biodefense/pandemic funding. Support removal of embryonic stem cell funding restrictions.

LobbyistCovered position, as disclosed
TODD E GILLENWATER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Support legislation (H.R. 1548) to provide for the approval of follow-on biologics (FOBs) that recognizes the complexity of large molecule product development and manufacturing, emphasizes patient safety, and contains adequate incentives for continued innovation. H.R. 1346/S. 540, Medical Device Safety Act. Oppose removal of medical device preemption provision from existing statute (HR 1346/S 540). Address concerns with application of comparative effectiveness research as a blunt cost containment tool and the consequences to biomedical innovation and patient access.

LobbyistCovered position, as disclosed
TODD E GILLENWATER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1346 (111th), S. 540 (111th), H.R. 1548 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.